Peripheral T-cell lymphoma (PTCL) is characterized by clinicopathologic heterogeneity with a frequently relapsing/refractory (R/R) course. The optimal sequencing and efficacy of novel agents and SCT in second-line and beyond remains yet to be determined. The objective of this dual-institution retrospective study is to assess outcomes in R/R nodal PTCL with respect to SCT and novel agents. A total of 148 patients were reviewed for baseline characteristics and treatment parameters. Endpoints were subsequent EFS (sEFS) and subsequent overall survival (sOS). The median sEFS and sOS for the entire cohort was 5.3 m (95% CI: 4.1 - 7.1) and 32.4 m (95% CI: 17.7 - 71.0), respectively. The median sEFS favored patients who received salvage SCT following either chemotherapy or novel agents (p = 0.005). The median sOS showed similar trend. Altogether, these data suggest that incorporation of novel agents in patients with and without SCT in second-line and beyond may improve outcomes compared to historical cohorts.
Keywords: Peripheral T-cell lymphoma; novel agents; outcomes; relapsed/refractory; stem cell transplantation.